Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer

Journal of Clinical Oncology

Volumn 20, Issue 22, 2002, Pages 4434-4439

  Shepherd, Frances A ^a   Giaccone, Giuseppe ^a   Seymour, Lesley ^a   Debruyne, Channa ^a   Bezjak, Andrea ^a   Hirsh, Vera ^a   Smylie, Michael ^a   Rubin, Sheldon ^a   Martins, Heidi ^a   Lamont, Alan ^a   Krzakowski, Maciej ^a   Sadura, Anna ^a   Zee, Benny ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; GEMCITABINE; KETOCONAZOLE; MARIMASTAT; METALLOPROTEINASE INHIBITOR; PACLITAXEL; PLACEBO; PRINOMASTAT; REBIMASTAT; TANOMASTAT;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; EUROPE; FEMALE; FOLLOW UP; HUMAN; LETHARGY; LIVER NECROSIS; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CANADA; CARCINOMA, SMALL CELL; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; EUROPE; FEMALE; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; MALE; METALLOENDOPEPTIDASES; MIDDLE AGED; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037112183     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.02.108     Document Type: Article

References (34)

1. Greenlee RT, Murray T, Bolden S, et al: Cancer statistics 2000. CA Cancer J Clin 50:7-33, 2000
2. National Cancer Institute of Canada: Canadian Cancer Statistics. Toronto, Canada, Canadian Cancer Society, 2000, pp 11-15
3. Travis WD, Linder J, Mackay B: Classification, histology, cytology and electron microscopy, in Pass HI, Mitchell JB, Johnston DH, et al (eds): Lung Cancer, Principles and Practice (Ed. 2). Philadelphia, PA, Lippincott Williams & Wilkins, 2000, pp 453-495
4. Feld R, Sagman U, LeBlanc M: Staging and prognostic factors for small cell lung cancer, in Pass HI, Mitchell JB, Johnston DH, et al (eds): Lung Cancer, Principles and Practice (Ed. 2). Philadelphia, PA, Lippincott Williams & Wilkins, 2000, pp 612-627
5. Carney DN, Shepherd FA: Treatment of small cell lung cancer: Chemotherapy, in Hansen HH (ed): The International Association for the Study of Lung Cancer Textbook of Lung Cancer. London, United Kingdom, Martin Dunitz Publishers, 2000, pp 261-272
6. Shepherd FA: The role of chemotherapy in the treatment of small cell lung cancer. Chest Surg Clinics of North America 7:113-133, 1997
7. Pignon JP, Arriagada R, Ihde DC, et al: A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 327:1618-1624, 1992
8. Ennis BW, Matrisian LM: Matrix degrading metalloproteinases. J Neuro-Oncol 18:105-109, 1994
9. Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260-1270, 1997
10. Khokha R, Denhardt DT: Matrix metalloproteinases and tissue inhibitor of metalloproteinases: A review of their role in tumorigenesis and tissue invasion. Invasion Metastasis 9:391-405, 1989
11. Kodate M, Kasai T, Ghashimoto H, et al: Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol International 47:461-469, 1997
12. Thomas P, Liu N, Khokha R, et al: Expression of matrix metalloproteinases and their tissue inhibitors in non-small cell lung cancer. J Pathol 190:150-156, 2000
13. Karameris A, Panagou P, Tsilalis T, et al: Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas: A molecular and immunohistochemical study. Am J Resp Crit Care Med 156:1930-1936, 1997
14. Gonzalez-Avila G, Iturria C, Vadillo F, et al: 72-kD (MMP2) and 92 kD (MMP9) type IV collagenase production and activity in different histologic types of lung cancer cells. Pathobiol 66:5-16, 1998
15. Kawano N, Osawa H, Ito T, et al: Expression of gelatinase A, tissue inhibitor of metalloproteinase-2, matrilysin and trypsinogen in lung neoplasms: An immunohistochemical study. Hum Pathol 28:613-622, 1997
16. Michael M, Babic B, Khokha R, et al: Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 17:1802-1808, 1999
17. Brown PD, Giavazzi R: Matrix metalloproteinase inhibition: A review of anti-tumour activity. Ann Oncol 6:967-974, 1995
18. Brown PD: Matrix metalloproteinase inhibitors: A novel class of anti-cancer agents. Advan Enzyme Regul 35:293-301, 1995
19. Cox DR: Regression models and life table (with discussion). J Royal Stat Soc B 74:187-220, 1972
20. Liotta LA, Kleinerman J, Catanzaro P, et al: Degradation of basement membrane by murine tumor cells. J Natl Cancer Inst 58:1427-1431, 1997
21. Liotta LA, Tryggvason K, Garbisa S, et al: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 287:67-68, 1980
22. Salo T, Liotta LA, Keski-Oja J, et al: Secretion of basement membrane collagen degrading enzyme and plasminogen activation by transformed cells: Role in metastasis. Int J Cancer 30:669-673, 1982
23. Brunner N, Pyke C, Hansen CH, et al: Urokinase plasminogen activator (uPA) and its type 1 inhibitor (pal-1): Regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer. Cancer Treat Res 71:299-309, 1994
24. Urbanski SJ, Edwards JR, Maitland A, et al: Expression of metalloproteinases and their inhibitors in primary pulmonary carcinoma. Br J Cancer 66:1188-1194, 1992
25. Tokuraku M, Sato H, Murakami S, et al: Activation of precursor of gelatinase A/72 kDa type IV collagenase/MMP 2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase [MT-MMP] and with lymph node metastasis. Int J Cancer 64:355-359, 1995
26. Fielding J, Scholefield J, Stuart R, et al: A randomized double-blind placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinoma. Proc Am Soc Clin Oncol 19:240a, 2000 (abstr 929)
27. Phuphanich S, Levin V, Yung W, et al: A multicenter, randomized, double-blind, placebo-controlled (PB) trial of marimastat (MT) in patients with glioblastoma multiforme or gliosarcoma following completion of conventional first-line treatment. Proc Am Soc Clin Oncol 20:52a, 2001 (abstr 205)
28. Bramhall S, Rosemurgy A, Brown PD, et al: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial. J Clin Oncol 19:3447-3455, 2001
29. Moore M, Hamm J, Eisenberg P, et al: A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY12-9566 in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 19:240a, 2000 (abstr 930)
30. Smylie M, Mercier R, Aboulafia D, et al: Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 20:307a, 2001 (abstr 1226)
31. Bissett D, O'Byrne K, von Pawel J, et al: Phase III study of the matrix metalloproteinase inhibitor prinomastat in combination with gemcitabine and cisplatin in non-small cell lung cancer. Proc Am Soc Clin Oncol 21:296a. 2002 (abstr 1183)
32. Ahmann F, Saad F, Mercier R, et al: Interim results of a phase III study of the matrix metalloproteinase inhibitor prinomastat in patients having metastatic hormone refractory prostate cancer. Proc Am Soc Clin Oncol 20:174a, 2001 (abstr 692)
33. Miller KD, Gradishar WJ, Schuchter LM, et al: A randomized phase II pilot trial of adjuvant marimastat in patients with early breast cancer. Proc Am Soc Clin Oncol 19:96a, 2000 (abstr 369)
34. Douillard J, Petersen V, Shepherd F, et al: Randomized phase II study of BMS-275291 versus placebo in patients with stage IIIB or IV non-small cell lung cancer receiving paclitaxel + carboplatin. National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Eur J Cancer 37:S19, 2001 (suppl 6, abstr 63)